Healthcare regulators in the United Kingdom gave the green light for AstraZeneca's COVID-19 vaccine clinical trial to resume Sept. 13 after a suspected spinal problem halted the study last week, WebMD reports.
Several media outlets, including The New York Times, reported that a trial participant had been diagnosed with transverse myelitis, a rare neurologic disorder.
The illness is an inflammation of the spinal cord that interrupts messages that nerves send throughout the body, according to Rochester, Minn.-based Mayo Clinic.
The U.S. portion of the clinical trial is enrolling 30,000 participants, but the study remains paused while safety data is being reviewed.
More than 18,000 individuals have received the vaccine so far, according to WebMD.